Insmed reports Q4 ARIKAYCE revenue $104.4M; brensocatib NDA accepted with Priority Review

INSMED Inc

2024-FY EPS reported -$5.57 revenue$363,707,000

Full-year 2024 ARIKAYCE revenue $363.7M (+19% YoY); Q4 net loss $235.5M ($1.32/share).
Brensocatib NDA for bronchiectasis accepted by FDA with Priority Review; PDUFA date Aug 12, 2025.
Company reiterates FY2025 ARIKAYCE revenue guidance $405M–$425M (11-17% YoY growth).
Cash, equivalents, and marketable securities approx. $1.4B as of Dec 31, 2024.
Director Alfred Altomari will not stand for re-election at 2025 Annual Meeting; no disagreement.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alfred Altomari

Director

INSM · INSMED Inc

Filed: February 20, 2025, 6:59 PM ET

On February 18, 2025, Alfred Altomari notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alfred Altomari departed as Director at INSMED Inc.

Action: will not stand for re-election
Role: Director

Exact text from the filing

On February 18, 2025, Alfred Altomari notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).

View on SEC.gov

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-25-005190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.